共 17 条
- [1] Shahinian VB(2005)Risk of fracture after androgen deprivation for prostate cancer N. Engl. J. Med. 352 154-164
- [2] Kuo YF(2007)Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial Ann. Intern. Med. 146 416-424
- [3] Freeman JL(2003)Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer J. Urol. 169 2008-2012
- [4] Goodwin JS(2010)Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer J. Urol. 184 1316-1321
- [5] Greenspan SL(2006)Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J. Clin. Oncol. 24 4448-4456
- [6] Nelson JB(2004)Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation Obstet. Gynecol. 104 837-844
- [7] Trump DL(2009)Denosumab in men receiving androgen-deprivation therapy for prostate cancer N. Engl. J. Med. 361 745-755
- [8] Resnick NM(2010)Intermittent androgen suppression for prostate cancer Nat. Rev. Urol. 7 552-560
- [9] Smith MR(undefined)undefined undefined undefined undefined-undefined
- [10] Smith MR(undefined)undefined undefined undefined undefined-undefined